Substance / Medication

Methenamine hippurate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women- a systematic review.
Kale Saurabh, Somani Bhaskar K · Curr Opin Urol · 2023
PMID: 37337660Meta-Analysis
Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis.
Bakhit Mina, Krzyzaniak Natalia, Hilder Joanne et al. · Br J Gen Pract · 2021
PMID: 34001538Meta-AnalysisFull text (PMC)
Methenamine hippurate for preventing urinary tract infections.
Lee Bon San B, Bhuta Tushar, Simpson Judy M et al. · Cochrane Database Syst Rev · 2012
PMID: 23076896Meta-AnalysisFull text (PMC)
Methenamine hippurate for preventing urinary tract infections.
Lee B B, Simpson J M, Craig J C et al. · Cochrane Database Syst Rev · 2007
PMID: 17943785Meta-Analysis
Methenamine hippurate for preventing urinary tract infections.
Lee B, Bhuta T, Craig J et al. · Cochrane Database Syst Rev · 2002
PMID: 11869659Meta-Analysis
Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women-a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU).
Heltveit-Olsen Silje Rebekka, Arnljots Egill Snaebjörnsson, Sundvall Pär-Daniel et al. · Clin Microbiol Infect · 2025
PMID: 40669691RCT
Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial.
Botros Carolyn, Lozo Svjetlana, Iyer Shilpa et al. · Int Urogynecol J · 2022
PMID: 34115162RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Methenamine hippurate (substance)
SNOMED CT
55741006
UMLS CUI
C0066105

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.